FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386021905> ?p ?o ?g. }

• W4386021905 endingPage "4485" @default.
• W4386021905 startingPage "4478" @default.
• W4386021905 abstract "The Atezo-Brain study evaluated atezolizumab combined with chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) with untreated brain metastases, a population traditionally excluded from trials.This single-arm phase II clinical trial enrolled patients with advanced nonsquamous NSCLC with untreated brain metastases without neurologic symptoms or asymptomatic with medical treatment. Dexamethasone was allowed up to 4 mg once daily. Atezolizumab plus carboplatin and pemetrexed was given for four to six cycles followed by atezolizumab plus pemetrexed until progression for a maximum of 2 years. The primary end points were to determine the progression-free survival (PFS) rate at 12 weeks and the incidence of grade ≥3 adverse events during the first 9 weeks. Intracranial outcomes were assessed using response assessment in neuro-oncology brain metastases criteria.Forty patients were enrolled and 22 (55%) were receiving corticosteroids at baseline. The overall 12-week PFS rate was 62.2% (95% credibility interval [CrI], 47.1 to 76.2). The rate of grade 3/4 adverse events during the first 9 weeks was 27.5%. Most neurologic events were grade 1 and 2 but five patients (12.5%) experienced grade 3-4 neurologic events. With a median follow-up of 31 months, intracranial median PFS was 6.9 months and response rate was 42.7% (95% CrI, 28.1 to 57.9). Systemic median PFS was 8.9 months and response rate was 45% (95% CrI, 28.1 to 57.9). The median overall survival (OS) was 11.8 months (95% CI, 7.6 to 16.9) and the 2-year OS rate was 27.5% (95% CI, 16.6 to 45.5).Atezolizumab plus carboplatin and pemetrexed demonstrates activity in patients with advanced nonsquamous NSCLC with untreated brain metastases with an acceptable safety profile." @default.
• W4386021905 created "2023-08-22" @default.
• W4386021905 creator A5006579116 @default.
• W4386021905 creator A5008290108 @default.
• W4386021905 creator A5013585698 @default.
• W4386021905 creator A5018144464 @default.
• W4386021905 creator A5029761367 @default.
• W4386021905 creator A5040894422 @default.
• W4386021905 creator A5049062198 @default.
• W4386021905 creator A5049754398 @default.
• W4386021905 creator A5056313396 @default.
• W4386021905 creator A5060914752 @default.
• W4386021905 creator A5064234791 @default.
• W4386021905 creator A5064603825 @default.
• W4386021905 creator A5066952204 @default.
• W4386021905 creator A5071730688 @default.
• W4386021905 creator A5079647211 @default.
• W4386021905 creator A5080915100 @default.
• W4386021905 creator A5082318012 @default.
• W4386021905 creator A5083097777 @default.
• W4386021905 date "2023-10-01" @default.
• W4386021905 modified "2023-10-18" @default.
• W4386021905 title "Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)" @default.
• W4386021905 cites W1841628176 @default.
• W4386021905 cites W2044200030 @default.
• W4386021905 cites W2143843774 @default.
• W4386021905 cites W2145376545 @default.
• W4386021905 cites W2492450141 @default.
• W4386021905 cites W2510132475 @default.
• W4386021905 cites W2569358221 @default.
• W4386021905 cites W2789821514 @default.
• W4386021905 cites W2912571746 @default.
• W4386021905 cites W3014209163 @default.
• W4386021905 cites W3042014810 @default.
• W4386021905 cites W3110814768 @default.
• W4386021905 cites W3164604407 @default.
• W4386021905 cites W3178873995 @default.
• W4386021905 cites W3207731879 @default.
• W4386021905 cites W4200190043 @default.
• W4386021905 doi "https://doi.org/10.1200/jco.22.02561" @default.
• W4386021905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37603816" @default.
• W4386021905 hasPublicationYear "2023" @default.
• W4386021905 type Work @default.
• W4386021905 citedByCount "5" @default.
• W4386021905 countsByYear W43860219052022 @default.
• W4386021905 countsByYear W43860219052023 @default.
• W4386021905 crossrefType "journal-article" @default.
• W4386021905 hasAuthorship W4386021905A5006579116 @default.
• W4386021905 hasAuthorship W4386021905A5008290108 @default.
• W4386021905 hasAuthorship W4386021905A5013585698 @default.
• W4386021905 hasAuthorship W4386021905A5018144464 @default.
• W4386021905 hasAuthorship W4386021905A5029761367 @default.
• W4386021905 hasAuthorship W4386021905A5040894422 @default.
• W4386021905 hasAuthorship W4386021905A5049062198 @default.
• W4386021905 hasAuthorship W4386021905A5049754398 @default.
• W4386021905 hasAuthorship W4386021905A5056313396 @default.
• W4386021905 hasAuthorship W4386021905A5060914752 @default.
• W4386021905 hasAuthorship W4386021905A5064234791 @default.
• W4386021905 hasAuthorship W4386021905A5064603825 @default.
• W4386021905 hasAuthorship W4386021905A5066952204 @default.
• W4386021905 hasAuthorship W4386021905A5071730688 @default.
• W4386021905 hasAuthorship W4386021905A5079647211 @default.
• W4386021905 hasAuthorship W4386021905A5080915100 @default.
• W4386021905 hasAuthorship W4386021905A5082318012 @default.
• W4386021905 hasAuthorship W4386021905A5083097777 @default.
• W4386021905 hasBestOaLocation W43860219051 @default.
• W4386021905 hasConcept C121608353 @default.
• W4386021905 hasConcept C126322002 @default.
• W4386021905 hasConcept C141071460 @default.
• W4386021905 hasConcept C143998085 @default.
• W4386021905 hasConcept C2775949291 @default.
• W4386021905 hasConcept C2776256026 @default.
• W4386021905 hasConcept C2776694085 @default.
• W4386021905 hasConcept C2777240266 @default.
• W4386021905 hasConcept C2777701055 @default.
• W4386021905 hasConcept C2778239845 @default.
• W4386021905 hasConcept C2780030458 @default.
• W4386021905 hasConcept C2781451048 @default.
• W4386021905 hasConcept C71924100 @default.
• W4386021905 hasConceptScore W4386021905C121608353 @default.
• W4386021905 hasConceptScore W4386021905C126322002 @default.
• W4386021905 hasConceptScore W4386021905C141071460 @default.
• W4386021905 hasConceptScore W4386021905C143998085 @default.
• W4386021905 hasConceptScore W4386021905C2775949291 @default.
• W4386021905 hasConceptScore W4386021905C2776256026 @default.
• W4386021905 hasConceptScore W4386021905C2776694085 @default.
• W4386021905 hasConceptScore W4386021905C2777240266 @default.
• W4386021905 hasConceptScore W4386021905C2777701055 @default.
• W4386021905 hasConceptScore W4386021905C2778239845 @default.
• W4386021905 hasConceptScore W4386021905C2780030458 @default.
• W4386021905 hasConceptScore W4386021905C2781451048 @default.
• W4386021905 hasConceptScore W4386021905C71924100 @default.
• W4386021905 hasIssue "28" @default.
• W4386021905 hasLocation W43860219051 @default.
• W4386021905 hasLocation W43860219052 @default.
• W4386021905 hasOpenAccess W4386021905 @default.
• W4386021905 hasPrimaryLocation W43860219051 @default.
• W4386021905 hasRelatedWork W2049286103 @default.

• next